Johnson & Johnson Vision Care, Inc. (including The Vision Care Institute™, LLC, Vistakon®, and Vistakon® Pharmaceuticals)

• Go to www.jnjvision.com

Vistakon, Division of Johnson & Johnson Vision Care, Inc. is a DIAMOND level sponsor of the American Optometric Association.

The Vistakon^® division of Johnson & Johnson Vision Care, Inc. specializes in disposable contact lenses marketed under the Acuvue^® brand name. "For over 20 years doctors and contact lens wearers have relied on the Acuvue brand to provide them with new and innovative vision correction products that best fit the overall comfort, eye health, and vision needs of the patient," says Pat Cummings, O.D., vice president, Professional Affairs.

Each new Acuvue product since 1987 has built on that first disposable lens to address gaps that exist in the marketplace. Acuvue Advance^® with Hydraclear^® meets the end-of-day comfort needs of the new patient with a healthy silicone hydrogel material. Acuvue Advance^® for Astigmatism, the most widely prescribed contact lenses for patients diagnosed with astigmatism, satisfies doctors' needs for an easy-to-fit, low-chair-time toric lens. Acuvue Oasys™ with Hydraclear^® Plus, the No. 1 silicone hydrogel lens on the market, is a breakthrough for contact lens wearers when their eyes feel tired and dry in challenging environments. Acuvue Oasys also has an additional indication by the U.S. FDA for therapeutic use as a bandage lens for certain acute and chronic ocular conditions. It is now available in a plano lens for therapeutic use. 1-Day Acuvue Moist™ contact lenses employ breakthrough Lacreon™ technology to lock in moisture all day.

All Acuvue Lenses offer effective UV-blocking, and Acuvue Advance, Acuvue Advance for Astigmatism, and Acuvue Oasys, which block more than 90 percent of UVA rays and 99 percent of UVB rays, are the first and only contact lenses that carry Seals of Acceptance for Ultraviolet Absorbing Contact Lenses from both the AOA and the World Council of Optometry. For information, call 800-843-2020 or visit www.ecp.acuvue.com.

Vistakon offers many services to help doctors educate patients and build their practices. Patients who register for the Acuminder™ online electronic contact lens reminder service can receive reminders by e-mail, text message, and/or computer desktop prompt. "Click-to-be-Contacted" facilitates the practitioner's responsibility for appointment scheduling for new contact lens patients. A new e-invoicing program allows online review of invoices and monthly statements. Doctors and staff can reprint past invoices and statements and dramatically improve reconciling their account.

Vistakon Pharmaceuticals specializes in the sales and marketing of ophthalmic pharmaceuticals, including: Alamast^® (pemirolast potassium ophthalmic solution) 0.1%, Betimol^® (timolol ophthalmic solution) 0.25% and .5%, Iquix^® (levofloxacin ophthalmic solution) 1.5%, and Quixin^® (levofloxacin ophthalmic solution) 0.5% through a co-marketing agreement with Santen Inc.

Commitment to optometrists and patients extends beyond products and services. The Vision Care Institute™ (www.tvciedu.com) is an innovative resource for optometry students and recent graduates. Headquartered in Jacksonville, Fla., the state-of-the-art facility lets participants experience the latest in vision diagnostic and treatment technologies through hands-on instruction.

Last year, TVCI introduced the AchieveVision™ Program to assess and help optimize athletes' visual skills in preparation for the Beijing 2008 Olympic Games. More than 175 U.S. Olympic athletes and hopefuls have gone through the assessments. TVCI, in partnership with the AOA, also supports InfantSEE^®, a no-cost public health program for infants. Educating the public about the importance of eye care exams as an integral part of health care at all ages and stages of life is a core component of the company's educational efforts. "We continue to support programs and initiatives that offer the potential to demonstrate improved and sustainable outcomes in eye health," said Dr. Cummings.